Prevalence and Health Outcomes of Clostridioides difficile Infection During the Coronavirus Disease 2019 Pandemic in a National Sample of United States Hospital Systems.

Background: The coronavirus disease 2019 (COVID-19) pandemic resulted in unprecedented emphasis on infection control procedures; however, it is unknown whether the pandemic altered Clostridioides difficile infection (CDI) prevalence. This study investigated CDI prevalence before and during the COVID-19 pandemic in a national sample of United States (US) hospitals.
Methods: This was a retrospective cohort study using the Premier Healthcare Database. Patients with laboratory-confirmed CDI from April 2019 through March 2020 (pre-COVID-19 period) and April 2020 through March 2021 (COVID-19 period) were included. CDI prevalence (CDI encounters per 10 000 total encounters) and inpatient outcomes (eg, mortality, hospital length of stay) were compared between pre-COVID-19 and COVID-19 periods using bivariable analyses or interrupted time series analysis.
Results: A total of 25 992 CDI encounters were included representing 22 130 unique CDI patients. CDI prevalence decreased from the pre-COVID-19 to COVID-19 period (12.2 per 10 000 vs 8.9 per 10 000, P < .0001), driven by a reduction in inpatient CDI prevalence (57.8 per 10 000 vs 49.4 per 10 000, P < .0001); however, the rate ratio did not significantly change over time (RR, 1.04 [95% confidence interval, .90-1.20]). From the pre-COVID-19 to COVID-19 period, CDI patients experienced higher inpatient mortality (5.5% vs 7.4%, P < .0001) and higher median encounter cost ($10 832 vs $12 862, P < .0001). Conclusions: CDI prevalence decreased during the COVID-19 pandemic in a national US sample, though at a rate similar to prior to the pandemic. CDI patients had higher inpatient mortality and encounter costs during the pandemic.

Clostridioides difficile infection (CDI) continues to be a major public health concern in hospitals worldwide and increasingly in the outpatient setting. CDI affects approximately half a million Americans annually, resulting in 29 000 deaths [1]. This devastating intestinal infection disproportionately affects patients recently exposed to antibiotics or other microbiome-disrupting therapies, those with poor immune response (eg, older age, severe underlying conditions, immunosuppression), and those with recent healthcare exposures (eg, hospitalization, nursing home residence) [2]. Prevention of CDI involves a combination of limiting unnecessary antibiotic exposure through antimicrobial stewardship efforts, preventing C difficile acquisition and transmission through infection control measures, and identifying CDI early and accurately through optimal diagnostic approaches [3, 4].

Since early 2020, the coronavirus disease (COVID-19) pandemic has become the most urgent threat to human health and has directly impacted several factors that may have influenced CDI epidemiology since this time. First, the pandemic has prompted unprecedented adherence to infection control practices, including hand hygiene, social distancing, masking, patient isolation, and more rigorous cleaning practices, which may have limited C difficile transmission [5-7]. Conversely, hospitals may have suffered high patient census in general and critical care wards, inadequate staffing, shortages of personal protective equipment, and prioritization of COVID-19 over traditional healthcare-associated infections, especially early in the pandemic and during surges [8-10]. Additionally, while studies have demonstrated a slight decrease in outpatient antibiotic prescribing since the pandemic [11], inpatient prescribing has increased [12]. In a systematic review and meta-analysis by Langford et al [13], 62.4% of all COVID-19 patients received at least 1 antibiotic agent. Of those, fluoroquinolones (20.0%), macrolides (18.9%), β-lactam/β-lactamase inhibitors (15.0%), and cephalosporins (15.0%) were the most prescribed antibiotics. Additionally, 8.6% of COVID-19 patients were reported to have concomitant bacterial infection, suggesting that many of these antibiotics prescribed may not have been necessary. Last, CDI diagnostics may have been affected recently as well. Given that diarrhea is a common symptom of COVID-19, clinicians may lack clinical suspicion of CDI in these patients, which may delay timely diagnosis and treatment and affect patient outcomes.

Prior studies have noted varying impact of the COVID-19 pandemic on CDI epidemiology. These predominantly single-center studies have either noted increased, decreased, or stable CDI prevalence over time and fewer have evaluated changes in patient outcomes or treatment patterns since the beginning of the pandemic. Therefore, the primary objective of this study was to compare the prevalence of CDI among a national sample of United States (US) hospital systems prior to and during the COVID-19 pandemic. Secondary outcomes included comparisons of CDI severity, treatment patterns, and health outcomes (eg, inpatient mortality, encounter costs, and hospital length of stay [LOS]).

METHODS

Data Source

This was a national, retrospective cohort study using data from the Premier Healthcare Database from 1 April 2019 to 31 March 2021. The Premier Healthcare Database collects data from more than 1041 academic and nonacademic hospitals, representing approximately 25% of all hospitals in the US, and includes >230 million unique patient visits [14]. While the exact location of each hospital is unavailable, hospitals are categorized by “provider region” as Midwest, Northeast, South, or West [11]. The database provides information on inpatient and outpatient encounters, including patient and facility characteristics, medications administered, diagnoses and procedures during the encounter, and financial data (eg, overall and treatment-specific charges and costs). Additionally, the database uses a masked identifier that allows for tracking patients longitudinally across encounters. The Premier Healthcare Database is considered exempt from institutional review board oversight.

Patient Population and Study Definitions

Premier Inc built the original dataset; all patients with an inpatient or outpatient diagnosis for CDI within the study period were eligible for inclusion. CDI was first identified using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 008.45 and International Classification of Diseases, Tenth Revision codes A04.71 or A04.72. This sample was then limited to those patients who had any positive C difficile stool test (eg, toxin enzyme immunoassay, glutamate dehydrogenase antigen, nucleic acid amplification test). The study period was classified as either pre–COVID-19 (1 April 2019 to 31 March 2020) or COVID-19 (1 April 2020 to 31 March 2021). The index visit was defined as the first encounter to include laboratory-confirmed CDI within the study period.

Patient baseline characteristics during the index visit included age, sex, race, ethnicity, and payor type. Facility characteristics included US Census region, rural or urban location, teaching status, and bed size. Additional CDI-related characteristics included inpatient or outpatient encounter, diagnosis type (admitting, primary, secondary), admission type (emergency, urgent, elective), severity indicators, and treatment patterns. An inpatient encounter is defined as a single visit that results in a patient being admitted to the hospital. An outpatient encounter is defined as a single visit to an outpatient clinic or emergency department. Each encounter is recorded as an individual event regardless of whether multiple encounters occurred on the same day. Serum creatinine (SCr) and white blood cell (WBC) count values were stratified according to the Infectious Diseases Society of America/Society for Healthcare Epidemiology of America guideline severity criteria if they occurred anytime during the encounter: SCr ≥1.5 mg/dL and WBC count >15 × 103 cells/µL [4]. Patients with either severity criterion were classified as “severe CDI.” CDI therapies included administration of at least 1 dose of the following agents during the encounter: metronidazole, oral vancomycin, fidaxomicin, bezlotoxumab, and fecal microbiota transplantation (FMT). These treatments were identified using Premier's standard charge code for each therapy. Total encounter costs were extracted from the patient cost variable provided by Premier, which represents the total cost to the hospital treating the patient during the encounter (includes all supplies, labor, equipment, etc). Last, for hospitalized patients only, hospital LOS was captured as a continuous variable and inpatient mortality was identified based on a discharge disposition of “expired.” This represents all-cause mortality.

Data and Statistical Analyses

Analyses were conducted using JMP 16 (SAS Institute, Cary, North Carolina) or StataMP 16 (StataCorp, College Station, Texas) software. CDI prevalence was determined by dividing the number of laboratory-confirmed CDI encounters for a given time period by the number of total patient encounters for any hospital system that contributed laboratory data during that same time period multiplied by 10 000. All recorded encounters within a given time period would be included in the number of total patient encounters for an “all encounters” analysis. We also repeated this calculation using index encounters only as the numerator and total unique patients as the denominator multiplied by 10 000. Monthly and total encounter and unique patient denominators were provided by Premier Inc. CDI rates and patient baseline characteristics were compared between the pre–COVID-19 and COVID-19 periods for index visits only. CDI severity, treatment characteristics, costs, and health outcomes for index encounters were compared between pre–COVID-19 and COVID-19 periods overall and by encounter type (inpatient vs outpatient) using the χ2 test for nominal dependent variables and the Wilcoxon rank-sum test for continuous, nonnormally distributed dependent variables. Outcome subgroup analyses were conducted by region, teaching hospital status, and rural or urban hospital status. Additionally, to evaluate for changes in CDI rates over time, an interrupted time series analyses was conducted using a generalized linear model assumed to follow a Poisson distribution allowing for overdispersion. All tests were 2-sided and performed at the 5% level of significance.

RESULTS

Population Characteristics

A total of 24.7 million patient encounters were available for analysis over the study period. Total patient encounters remained relatively stable throughout the study period (approximately 1.1 million in April 2019 and March 2021) with the exception of early in the pandemic period when encounters were lower (average 0.8 million encounters from March to May 2020). Using administrative codes only, a total of 149 189 CDI encounters were identified. Of these, 25 992 encounters included laboratory-confirmed CDI, representing 22 139 unique CDI patients/index encounters. CDI patient characteristics during the index encounter are provided in Table 1. CDI patients were predominantly older (median age, 68 years), female (57.5%), and White (79.5%). Comparisons of characteristics between study periods demonstrated numerically small but statistically significant differences in race, ethnicity, payor type, region, admission type, CDI diagnosis type, CDI present on admission, teaching and urban hospital status, and hospital bed size due to the large sample size.

Table 1.

Patient and Visit Characteristics of Clostridioides difficile Infection Index Encounters

Characteristic	Overall(N = 22 139)	Pre–COVID-19(n = 12 878)	COVID-19(n = 9261)	P Value
Age, y, median (IQR)	68 (56–78)	67 (54–78)	68 (57–78)	.3775
Female sex	57.5	59.2	57.7	.3678
Race				.0206
White	79.5	79.1	79.6
Black	12.3	11.2	12.5
Asian	1.7	1.3	1.8
Other	4.8	6.6	4.2
Unknown	1.8	1.8	1.8
Hispanic ethnicity	5.9	7.8	6.4	.0001
Payor				.0007
Medicare	64.2	64.2	64.3
Medicaid	11.5	11.4	11.7
Managed care	14.3	14.7	13.8
Commercial	3.7	3.8	3.7
Indigent/charity/self-pay	3.4	3.5	3.2
Other	2.9	2.5	3.4
US Census region				.0010
Midwest	22.3	22.0	22.6
Northeast	12.6	12.4	12.8
South	62.4	62.4	62.4
West	2.8	3.1	2.3
Inpatient admission	86.7	86.4	87.2	.0846
Admission type				<.0001
Emergency	80.1	70.2	81.0
Urgent	9.8	12.4	9.4
Elective	8.6	14.4	8.2
Trauma	0.5	0.4	0.6
Unknown	1.0	2.3	0.7
CDI diagnosis type				<.0001
Admitting	10.5	11.5	9.0
Primary	23.0	24.3	21.1
Secondary	66.6	64.2	69.9
CDI present on admission	59.3	59.6	59.0	<.0001
Teaching hospital	47.3	46.4	48.7	.0009
Urban hospital	83.5	84.3	82.3	.0001
Hospital bed size				.0002
0–99	7.8	7.6	8.1
100–199	14.7	15.1	14.2
200–299	16.0	15.7	16.3
300–399	18.9	19.5	18.1
400–499	11.8	12.2	11.2
≥500	30.9	29.9	32.2

Data are presented as % unless otherwise indicated.

Abbreviations: CDI, Clostridioides difficile infection; COVID-19, coronavirus disease 2019; IQR, interquartile range.

CDI Prevalence and Characteristics

CDI prevalence between time periods is depicted in Figure 1. CDI prevalence significantly decreased from the pre–COVID-19 to the COVID-19 period (12.2 per 10 000 vs 8.9 per 10 000, P < .0001). This was driven primarily by a reduction in inpatient CDI prevalence (57.8 per 10 000 vs 49.4 per 10 000, P < .0001), though outpatient CDI prevalence decreased as well (2.2 per 10 000 vs 1.5 per 10 000, P < .0001). These trends were similar when limiting to index visits alone: overall prevalence (12.1 per 10 000 vs 8.7 per 10 000), inpatient prevalence (52.8 per 10 000 vs 43.8 per 10 000), and outpatient prevalence (1.7 per 10 000 vs 1.1 per 10 000). Monthly CDI prevalence for all encounters and index encounters is presented in Figure 2. Overall, CDI prevalence for all encounters decreased over the study period from 13.3 per 10 000 in April 2019 to 6.7 per 10 000 in March 2021. This was mainly driven by decreasing trends in inpatient prevalence (64.6 per 10 000 vs 39.1 per 10 000), while outpatient prevalence decreased as well (2.4 per 10 000 vs 1.3 per 10 000). These trends were similar when limiting to index visits only: overall prevalence (14.7 per 10 000 vs 6.8 per 10 000), inpatient prevalence (65.0 per 10 000 vs 35.9 per 10 000), and outpatient prevalence (2.5 per 10 000 vs 1.1 per 10 000). Notably, interrupted time series analysis indicated no significant difference in the rate ratio (RR) from the pre–COVID-19 to COVID-19 period for all encounters (RR, 1.04 [95% confidence interval {CI}, .90–1.20]; P = .570) or inpatient encounters (RR, 1.08 [95% CI, .98–1.19]; P = .115).

Figure 1.

Clostridioides difficile infection (CDI) prevalence in the pre–coronavirus disease 2019 (COVID-19) and COVID-19 periods.

Figure 2.

Monthly Clostridioides difficile infection (CDI) prevalence over the study period. A, All CDI encounters. B, Index CDI encounters only.

During the index encounter, CDI was more commonly the primary diagnosis during the pre–COVID-19 period compared to the COVID-19 period (24.3% vs 21.1%, P < .0001), reflecting a shift to secondary diagnosis during the COVID-19 period (64.2% vs 69.9%, P < .0001) (Table 1).

For index encounters, the percentage of patients with severe CDI increased slightly from the pre–COVID-19 to COVID-19 period (41.3% vs 44.0%, P = .0003), driven primarily by an increase in the percentage of patients with WBC count >15 × 103 cells/µL (19.6% vs 22.0%, P = .0001) (Table 2). When stratified by visit type, only inpatients experienced a significant increase in the percentage of patients with severe CDI over time (43.2% vs 45.8%, P = .0007).

Table 2.

Clostridioides difficile Infection Characteristics and Health Outcomes During Index Visit

Characteristic	Overall	Pre–COVID-19	COVID-19	P Value
	(N = 22 139)	(n = 12 878)	(n = 9261)
Overall population
Severity indicators, %[a]
SCr ≥1.5 mg/dL	26.9	26.4	27.5	.0670
WBC count >15 × 103/µL	20.6	19.6	22.0	.0001
Severe CDI	42.4	41.3	44.0	.0003
CDI therapies, %[b]
Metronidazole	40.1	41.2	38.6	.0001
Oral vancomycin	79.0	77.6	81.0	<.0001
Fidaxomicin	5.7	6.2	5.1	.0003
Bezlotoxumab	<0.1	<0.1	<0.1	.0610
FMT	0.2	0.3	<0.1	<.0001
Cost (USD), median (IQR)	11 661 (5531–27 298)	10 834 (5231–2523)	12 862 (6054–30 473)	<.0001
Outpatients	(n = 2945)	(n = 1756)	(n = 1189)
Severity indicators, %[a]
SCr ≥1.5 mg/dL	12.3	11.8	12.9	.4653
WBC count >15 × 103/µL	12.6	12.3	13.0	.6756
Severe CDI	24.4	23.5	25.7	.2904
CDI therapies, %[b]
Metronidazole	13.4	13.1	14.0	.5011
Oral vancomycin	34.9	32.6	38.2	.0020
Fidaxomicin	1.1	1.4	0.7	.0661
Bezlotoxumab	0.0	0.0	0.0	1.0000
FMT	<0.1	<0.1	0.0	.3091
Cost (USD), median (IQR)	733 (83–2800)	637 (75–2462)	875 (89–3309)	<.0001
Inpatients	(n = 19 194)	(n = 11 122)	(n = 8072)
Severity indicators, %[a]
SCr ≥1.5 mg/dL	28.3	27.7	29.0	.0682
WBC count > 15 × 103/µL	21.5	20.5	22.9	.0002
Severe CDI	44.3	43.2	45.8	.0007
CDI therapies, %[b]
Metronidazole	44.2	45.6	42.2	<.0001
Oral vancomycin	85.8	84.7	87.3	<.0001
Fidaxomicin	6.4	7.0	5.7	.0005
Bezlotoxumab	<0.1	0.1	<0.1	.0589
FMT	0.2	0.4	<0.1	<.0001
Cost (USD), median (IQR)	14 194 (7372–31 514)	13 142 (6901–29 130)	15 682 (8056–34 657)	<.0001
Health outcomes
Inpatient mortality, %	6.3	5.5	7.4	<.0001
Length of stay, median (IQR)	7 (4–13)	7 (4–13)	7 (4–14)	<.0001

Abbreviations: CDI, Clostridioides difficile infection; COVID-19, coronavirus disease 2019; FMT, fecal microbiota transplantation; IQR, interquartile range; SCr, serum creatinine; USD, United States dollars; WBC, white blood cell.

Not all patients had documented laboratory values; percentages were calculated using the patients with a documented laboratory value as the denominator.

Patients may have received >1 CDI therapy; rows may add to >100%.

CDI treatment patterns during the index visit shifted slightly over the time period as well, with greatest numeric change seen with the increased use of oral vancomycin (77.6% vs 81.0%, P < .0001) and declines in fidaxomicin use (6.2% vs 5.1%, P = .0003), metronidazole use (41.2% vs 38.6%, P = .0001), and FMT use (0.3% vs <0.1%, P < .0001) during the COVID-19 period (Table 2).

Patient Health Outcomes

Patient costs significantly increased by an average of approximately $2000 from the pre–COVID-19 to COVID-19 period (P < .0001), driven primarily by inpatient treatment costs (Table 2). Among inpatient encounters only, all-cause mortality increased from the pre–COVID-19 to COVID-19 period (5.5% vs 7.4%, P < .0001). while median hospital LOS was numerically similar (7 days). These outcomes were worse for those presenting with severe CDI compared to nonsevere CDI: median patient costs ($16 762 vs $10 642, P < .0001), median hospital LOS (8 days vs 6 days, P < .0001), and mortality (10.6% vs 2.8%, P < .0001). Outcomes were also worse overall in the West region (median LOS, 9 days; mortality 10.0%) and among teaching hospitals (median LOS, 7 days; mortality 6.6%).

DISCUSSION

In this nationally representative study, CDI prevalence decreased from the pre–COVID-19 to the COVID-19 period; however, the rate of decline did not significantly change over time. During the COVID-19 period, patients with a CDI diagnosis confirmed with laboratory results experienced higher mortality and costs. Additionally, we noted a change in CDI treatment patterns, especially the limited use of FMT during this time. This study is strengthened by its large, multicenter design and inclusion of longitudinal inpatient and outpatient encounters that enhance the generalizability to the US population.

Several prior studies have evaluated the impact of the COVID-19 pandemic on CDI prevalence. Most have demonstrated a decline in CDI prevalence similar to our study [15-19], but some others have noted increased [20, 21] or stable prevalence/incidence [22, 23]. The studies with differing results diverge in design from the current study in a variety of ways including location of study, number of patients, types of patients, and time period examined. Furthermore, all of these studies were single-center studies with much smaller sample sizes. For example, Sandhu et al examined CDI rates in a metropolitan medical center in Detroit, Michigan, and found an increase from January–February 2020 to March–April 2020 (3.3 vs 3.6 per 10 000 patient-days) [20]. Similarly, another study demonstrating an increase in CDI trends by Baccolini et al studied only ICU patients at a single center in Rome, Italy, and recorded very few CDI patients in their cohorts (2019 cohort: 0/14 patients vs 2020 cohort: 2/45 patients) [21]. Last, studies by Luo et al and Hawes et al noted stable trends in CDI incidence, and both observed a decrease in diagnostic testing either due to masked symptoms by gastrointestinal symptoms caused by COVID-19 or a less perceived need to test after precautions were enforced [22, 23]. One of the largest published studies using data from the National Healthcare Safety Network noted a slight decline in the CDI standardized infection ratio from 2019 to 2020, which then remained stable throughout 2020 [24]. Similarly, Bentivegna et al found that the prevalence of hospital-acquired CDI was significantly lower during the COVID-19 pandemic compared to 2017 (odds ratio [OR], 2.98; P = .002), 2018 (OR, 2.27; P = .023), and 2019 (OR, 2.07; P = .047) [17]. This prior study and the current study support that CDI prevalence has decreased in recent years, though the rate of decline may not have been significantly affected by the pandemic. Interestingly, we did note 2 minor spikes in CDI rates during the COVID-19 period (April 2020 and October 2020) that may coincide with major COVID-19 waves in the US.

The continued decline in CDI prevalence during the pandemic may be due to several factors. First, the pandemic has prompted better adherence to infection control practices (eg, improved hand hygiene, donning of personal protective equipment, patient isolation) in hospitals and new practices in the outpatient setting (eg, masking, social distancing), which may have limited C difficile transmission. In addition, CDI rates have been declining in general in recent years due to enhanced antimicrobial and diagnostic stewardship efforts. Utilizing the CDC's Emerging Infections Program, a study by Guh et al reported that CDI incidence decreased from 2011 to 2017 for all CDI (154.9–143.6 per 100 000 population) and for healthcare-associated and community-associated CDI; however, after adjusting for nucleic acid amplification testing use to the 2011 rate (55%), overall and healthcare-associated CDI estimated incidence decreased while community-associated CDI incidence did not significantly change [1]. While this study cannot directly assess the cause of the decline in infection rates both before and during the pandemic, it is possible that diagnostic stewardship efforts utilized before COVID-19, such as 2-step testing, were extended into the COVID-19 period to reduce inappropriate testing and overdiagnosis. Next, recent studies have shown that hospitalizations for a variety of non–COVID-19 acute conditions have decreased despite there being a risk for the patient to avoid adverse outcomes, potentially due to patients’ desire to avoid the contagion by waiting to seek out care [25]. A study by Splinter et al [26] found that 20% of their patient population avoided healthcare during the COVID-19 pandemic despite a third of those patients reporting having had symptoms severe enough to warrant urgent care. In addition, CDI testing may have been impacted by the pandemic. It is estimated that 1 in 5 COVID-19 patients experiences gastrointestinal symptoms [27], which may impact clinical suspicion of CDI in these patients. Additionally, some single-center studies have reported a decline in CDI stool testing during the pandemic [19, 23]. This may be due to transition of care for some patients to the outpatient setting or possible concern about the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the stool [28]. Ultimately, it may be that these factors outweighed the impact of increased hospitalizations, critical illness, and antibiotic use during the pandemic. Interestingly, other healthcare-associated infections, including central line–associated bloodstream infections, catheter-associated urinary tract infection, ventilator-associated events, and methicillin-resistant Staphylococcus aureus bacteremia have significantly increased during the pandemic [24].

While this study noted a decline in CDI prevalence during the pandemic, more patients diagnosed with CDI during the pandemic experienced severe CDI and mortality. This could have led to higher treatment costs in the COVID-19 period as well, as severe CDI was associated with higher patient costs. Few prior studies have evaluated changes in these outcomes. One study by Granata et al [29] highlighted significant complications among patients with concomitant CDI and COVID-19 compared to COVID-19 alone. CDI patients experienced more complications at discharge (eg, pressure ulcers, chronic heart decompensation), longer hospital LOS (35 vs 19 days, P = .0007), increased values for CDI severity indicators (ie, WBC, SCr), and higher mortality (28.9% vs 21.9%, P = .1). These poorer outcomes disproportionately affected older, frail patients with previous antibiotic and healthcare exposures. Another case report noted severe CDI as a potential late complication of COVID-19 [30]. Although we were unable to determine coinfection with COVID-19 among our CDI cohort, presumably coinfection would likely have impacted CDI severity and patient outcomes during the pandemic. This is also consistent with the shift to more secondary CDI diagnosis compared to admitting or primary CDI diagnoses during the pandemic in our study. Consequently, it is possible that only patients with severe cases would have been admitted to healthcare facilities and potentially make up a larger percentage of admitting and primary CDI diagnosis types than in the pre–COVID-19 period.

During the pandemic, this study found notable changes in CDI treatment patterns. For example, oral vancomycin use increased during the pandemic, while fidaxomicin, metronidazole, and FMT use decreased. These changes do not reflect newer recommendations made by the updated CDI clinical practice guidelines [4], and the use of front-line agents (eg, fidaxomicin, bezlotoxumab) remains low. Perhaps the most striking treatment pattern was the decline in FMT use during the pandemic. Studies have demonstrated the presence of SARS-CoV-2 in the stool and the potential to transmit COVID-19 through FMT [25]. This led to an update by the US Food and Drug Administration to recommend using only stool donated prior to 1 December 2019 [28, 31]. This also prompted temporary inaccessibility of FMT product from US-based stool banks (eg, OpenBiome), highlighting the need for more rigorous screening of donor stool and US Food and Drug Administration–approved, commercially available microbiota replacement therapies.

This study has potential limitations. First, this study utilized a retrospective design and data collected from electronic medical records. This design may be subject to errors in documentation of patient and treatment characteristics. Administrative coding was used to initially identify CDI patients, then diagnosis was confirmed with a positive stool test. It is possible that some CDI cases were missed using this method (eg, lack of a CDI administrative code). This study may also be subject to ascertainment bias whereby fewer C difficile laboratory tests may have been conducted during the COVID-19 period. Nucleic acid amplification testing alone, which was allowed in this study, may have potentially misclassified some C difficile colonizers as CDI. Furthermore, metronidazole use for CDI may be overestimated since metronidazole may be used for non-CDI indications. We were unable to define community or hospital-onset CDI because the specific surveillance definitions in Premier lack exact timing of diagnosis. CDI diagnosis type (eg, admitting, primary, secondary) was used as a surrogate marker to estimate these surveillance definitions. COVID-19 administrative codes and instruction on their use were made available on 1 April 2020 by the CDC. Given that these codes were unavailable during part of the study period with potentially varying uptake by healthcare systems, it was not possible to quantify coinfection with COVID-19. Additionally, the Premier Inc COVID-19 Special Release as well as data beyond that originally acquired (through March 2021) was unavailable without purchase, further making it difficult to determine whether there was a causative association between CDI prevalence and health outcomes and our ability to validate these findings with more recent data. Next, specific information regarding infection control practices and population-level characteristics (eg, antibiotic use, other CDI risk factors) was unavailable; thus, we were unable to determine causative or risk factors associated with changes in CDI prevalence or outcomes over time. Last, only healthcare systems that contributed data to Premier Inc were included for analysis and results might not be generalizable to noncontributing hospitals, including Veterans Affairs facilities.

CONCLUSIONS

Overall, CDI prevalence decreased during the COVID-19 pandemic in a national US sample of hospitals; however, this decrease was similar to declining rates prior to the pandemic and does not provide direct evidence that the pandemic directly influenced CDI prevalence. CDI patients also experienced higher inpatient mortality and costs during the pandemic. Further studies are needed to identify the specific factors that contributed to changes in CDI prevalence and health outcomes, such that targeted interventions can be maintained or created in the future to prevent and treat CDI effectively.